Ocuphire Pharma (OCUP)
(Real Time Quote from BATS)
$1.51 USD
-0.02 (-1.31%)
Updated Apr 25, 2024 11:58 AM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
OCUP 1.51 -0.02(-1.31%)
Will OCUP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for OCUP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCUP
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
OCUP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
Other News for OCUP
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Ocuphire Pharma announces enrollment of first patient in LYNX-2 Phase 3 study
12 Health Care Stocks Moving In Thursday's After-Market Session